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phism in intron 3 of IL-4 gene was analyzed through PCR. Analysis of 
data was performed using the computer software SPSS for windows. 
Results: A twofold increased risk for NSCLC progression (from early 
I/II stages to III/IV advanced stages of the disease) was observed for 
G carrier genotypes of -2518 MCP-1 polymorphism (P=0.028). This 
result was conﬁrmed in an age and sex adjusted multivariate logistic 
regression analysis (aOR=2.30; P=0.014). Considering the inﬂuence 
of IL-4 intron 3 polymorphism, our results do not demonstrate any 
association between -2518 MCP-1 G carrier genotypes in the risk to 
NSCLC (P=0.104). Furthermore, no statistically signiﬁcant association 
was found between IL-4 intron 3 VNTR polymorphism and NSCLC 
progression (P=0.154).
Conclusion: The preliminary results of this study indicate that the 
polymorphism -2518 MCP-1 promotes NSCLC progression, regardless 
sex and age and there is no association between IL-4 intron 3 poly-
morphism and NSCLC progression. Immunotherapy is a promising 
approach for the development of integrative therapies for cancer and 
chemokine antagonists might be useful for the treatment of cancer. The 
identiﬁcation of novel therapies designed to minimize the effects of 
MCP-1 in tumor progression should be the focus of further research.
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Background: Bronchioloalveolar carcinoma (BAC) is a subtype of 
non-small cell lung cancer (NSCLC) with distinct clinical features, 
tumor biology, response to therapy and prognosis. The disease is 
commonly multifocal, presenting as numerous nodules that are either 
conﬁned to a single lobe or distributed among several lobes of the 
lung. Primary management of multifocal BAC remains controversial 
and may include close surveillance, surgical resection and/or systemic 
therapy. Knowledge of current practice patterns and outcomes may help 
to deﬁne an optimal treatment modality. 
Methods: All patients diagnosed with pure BAC or NSCLC with BAC 
features at a major cancer center between January 2001 and Decem-
ber 2005 were identiﬁed from the hospital cancer registry and central 
pathology database. Corresponding medical records were reviewed for 
demographic parameters, disease characteristics, treatment modality 
and clinical outcomes. 
Results: In total, 109 patients with pure BAC or NSCLC with BAC 
features were identiﬁed. Twenty-four patients were excluded due to al-
ternate diagnoses, early recurrent or progressive disease, or transfer of 
care to other facilities, leaving 85 patients who were eligible for study. 
The mean age at diagnosis was 64.2 years, 54 (63.5%) were females, 
and 56 (65.9%) were smokers. At diagnosis, 22 (25.9%) were stage IA 
to IIIA and 63 (74.1%) were stage IIIB or IV. Of the 63 patients with 
multifocal BAC, 15 (23.8%) had disease conﬁned to one lobe while 48 
(76.2%) had multiple lobes involved. The primary treatment modality 
for multifocal disease included surgical resection in 49 (77.8%), sys-
temic therapy in 9 (14.2%) and observation in 5 (8.0%) cases. Among 
the 9 patients treated with systemic therapy, 6 had disease in 3 or more 
lobes, 5 received cytotoxic chemotherapy and 4 received epidermal 
growth factor receptor (EGFR) inhibitors. Median follow-up was 25.2 
months. Among the 49 patients who underwent resection, only 19 
(38.8%) developed a recurrence, most commonly in the lung (16) and 
brain (3). Recurrent or progressive disease occurred in 7/9 patients in 
the systemic therapy group and 1/5 patients in the observation group. 
Conclusions: Surgery and observation continue to be reasonable treat-
ment options for selected patients with multifocal BAC. The apparent 
lack of beneﬁt of systemic therapy in this series may reﬂect selection 
bias in referral patterns and treatment choice where only those with 
more aggressive disease (3 or more lobes involved) received cytotoxic 
agents or EGFR inhibitors. The role of systemic therapy in multifocal 
BAC deserves further prospective evaluation.
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Background: Therapies directed at both the epidermal growth factor 
receptor (EGFR) and the vascular endothelial growth factor (VEGF) 
pathways have been shown to improve survival in NSCLC. Inhibitors 
of these pathways also have radiosensitizing effects.
Methods: We are conducting a phase I/II trial incorporating B and Er 
into a strategy of I and C CbP in stage III NSCLC. Pts receive 2 cycles 
of I Cb (AUC 6), P (225 mg/m2) and B (15 mg/kg) on days 1 and 22. 
PET scans are done pre- and post-I. On day 43, pts receive weekly Cb 
(AUC 2 x 7) and P (45 mg/m2 x 7) with 74 Gy (2 Gy/d) of thoracic con-
formal radiotherapy. Cohort I (n=5) receives B at 10 mg/kg q2wks dur-
ing C therapy. Cohorts II and III (both n=5) receive the same dose of 
B as in cohort I but also receive Er at 100 mg and 150 mg po Tuesday 
- Friday of each week of C therapy, respectively. Consolidation therapy 
is then administered 3-6 weeks after completion of C therapy with Er 
(150 mg po qd) and B (15 mg/kg q3wk) for 6 cycles. Once phase I is 
complete, phase II expansion will occur. The primary endpoint is PFS 
at 1 year. All histologies are allowed including squamous.
Results: Thus far, 10 PS 0-1 pts (Cohorts I and II) have been accrued 
(med age 59 yrs, range 41-69, 6 Adeno, 4 Squamous, 7 IIIA, 3 IIIB, 3 
Never/Light smokers). All 10 pts have completed I CbP + B with one 
gr 3-4 non-hematologic toxicity (gr 3 hypertension). No pulmonary 
hemorrhage has been seen (including the 4 squamous cell pts).Thus 
far, nine have been evaluated for response (4 PR, 5 SD). In Cohort I, 
all 5 pts started C therapy on day 43 and all 5 completed therapy to 
